Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2022-06-13 Director's Dealing
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - CW 3 pages 180.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the change (on-market trade), and dates. This is a formal notification of a director's personal share transactions. The document is about a director's dealing in company shares, not a financial report or announcement of a report. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length is 4245 characters, which is consistent with a detailed notice rather than a brief announcement or a full report.
2022-06-13 English
Change of Director's Interest Notice - LR 2 pages 377.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares and options held before and after the change, nature of the change, and confirms no trading during a closed period without clearance. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 4144 characters, consistent with a detailed notice but not a full financial report. Therefore, the correct classification is DIRS.
2022-06-08 English
Application for quotation of securities - IMU 12 pages 40.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Imugene Limited. It details the issuance and conversion of options into ordinary fully paid shares, including the number of securities, issue dates, prices, and whether they are held by key management personnel. The document is focused on the issuance and quotation of new shares resulting from exercised options and convertible securities. There is no indication of financial performance data, management discussion, earnings, or other report types. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes.
2022-06-07 English
Notice Under Section 708A 1 page 133.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 8 June 2022, providing a notice under Section 708A(5)(e) of the Corporations Act 2001. It details the issuance of ordinary shares without disclosure under Part 6D.2 of the Corporations Act, compliance with relevant sections of the Corporations Act, and confirms no excluded information is required to be disclosed. The content focuses on share issuance and compliance notices related to capital raising activities. The document length is short (1285 characters) and it is a formal regulatory announcement about share issuance rather than a full financial report or detailed capital structure update. Given the nature of the notice about share issuance and compliance under the Corporations Act, this fits best under Capital/Financing Update (CAP).
2022-06-07 English
IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD 3 pages 127.9KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement regarding the appointment of a new member to the Scientific Advisory Board and the resignation of the Chief Medical Officer. It contains no financial data, no report or financial statements, and no mention of voting results or regulatory certifications. The content is focused on management and board changes, specifically senior scientific advisory appointments and executive resignations. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4860 characters, which is consistent with a typical announcement rather than a full report.
2022-05-31 English
IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 2 pages 124.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the publication of an abstract related to their Phase 1 CHECKVacc trial at the ASCO 2022 Annual Meeting. It provides a summary of the abstract's title, the principal investigator, and a link to the abstract. The document is short (3110 characters) and serves as a notification of the publication of research findings rather than a detailed report or financial document. It does not contain financial data, management discussion, or regulatory filings. It is an announcement of a publication rather than the publication itself. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2022-05-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.